FBRX (FBRX)
Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Forte Biosciences, Inc. — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing from Forte Biosciences, which is essentially a press release they sent to investors and the SEC. It's announcing their full-year 2025 financial results and giving an update on their drug development progress. Think of it as a company's "state of the u
SEC filings
All filings →Insider trades
All insider trades →FBRX has no reported insider trades in the last 90 days.